Helping the eye's nerve cells survive and regrow after injury

Activity-related mechanisms of selective retinal ganglion cell resilience and axon regeneration

NIH-funded research Baylor College of Medicine · NIH-11094028

This project develops ways to help retinal ganglion cells — the eye's nerve cells — survive damage and regrow their connections to benefit people with glaucoma or optic nerve injuries.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionBaylor College of Medicine NIH-funded
Lab location1 site (Houston, United States)
Project IDNIH-11094028 on NIH RePORTER

What this research studies

From a patient's point of view, researchers are studying why some retinal ganglion cells die after injury while others survive and try to regrow their nerve fibers. They will use advanced lab experiments, mostly in preclinical animal models, to compare different cell types and to test how increasing nerve activity and specific molecular signals (like cAMP and calcium) affect survival and regeneration. The team combines genetic, physiological, and imaging methods to pinpoint the molecular switches that make some cells resilient. Findings are meant to guide future treatments that could protect vision or encourage recovery after optic nerve damage.

Who could benefit from this research

Good fit: Adults with glaucoma or recent optic nerve injury are the kinds of patients who could eventually be eligible for related clinical trials based on this work.

Not a fit: People with vision loss from other retinal diseases that do not involve retinal ganglion cell degeneration (for example primary macular degeneration) or those with very long-standing complete vision loss may not benefit from these approaches.

Why it matters

Potential benefit: If successful, this work could point to new treatments that protect retinal neurons and promote nerve regrowth, potentially preserving or restoring vision in glaucoma and optic nerve injury.

How similar studies have performed: Previous animal studies have shown that boosting retinal ganglion cell activity or targeting certain molecular pathways can improve survival or axon regrowth in some cell types, but effects have been limited and have not yet restored vision.

Where this research is happening

Houston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.